Journal of Clinical & Experimental Pathology

Laroche R, J Clin Exp Pathol 2024, 14:4

Opinion Article Open Access

Implications of Chromosomal Translocations in Multiple Myeloma for Disease Progression and Prognosis

Rebecca Laroche*

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

***Corresponding author:** Rebecca Laroche, Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands, E-mail: reblar@LUMC.nl

Received: 27-Jun-2024, Manuscript No. JCEP-24-143847; **Editor assigned:** 01-Jul-2024, PreQc No. JCEP-24-143847 (PQ); **Reviewed:** 15-Jul-2024, QC No. JCEP-24-143847; **Revised:** 22-Jul-2024, Manuscript No. JCEP-24-143847 (R); **Published:** 29-Jul-2024, DOI: 10.4172/2161-0681.24.14.507

Citation: Laroche R (2024) Implications of Chromosomal Translocations in Multiple Myeloma for Disease Progression and Prognosis. J Clin Exp Pathol. 14:507.

Description

An increase of aberrant plasma cells in the bone marrow is the feature of Multiple Myeloma (MM), a malignant plasma cell condition. The prognosis for MM patients varies greatly, and the disease is still incurable even though improvements in treatment. Cytogenetic abnormalities are important because they affect the course of the disease and direct therapeutic approaches. Several chromosomal abnormalities are linked to multiple myeloma, which may have an impact on the course of the disease and how well it responds to treatment. Chromosome 14q32 is the most frequent cytogenetic change associated with Multiple Myeloma (MM) is a translocation involving chromosome 14q32, where the immunoglobulin heavy chain locus is positioned between distinct partner genes. The translocations t(4;14), t(11;14), and t(14;16) are the most commonly observed. There are unique prognosis implications for each of these translocations. The immunoglobulin locus is aligned with the FGFR3 (Fibroblast Growth Factor Receptor 3) or MMSET (Multiple Myeloma Set Domain) gene as a result of the t(4;14) translocation. Because of its effect on cell survival and proliferation, it is linked to a bad prognosis.

Cyclin D1 is overexpressed as a result of the t(11;14) translocation, which encourages cell cycle advancement. When compared to other high-risk anomalies, it is linked to a better prognosis, albeit actual results may differ depending on additional circumstances. The t(14;16) translocation causes the oncogene MAF (musculoaponeurotic fibrosarcoma) to be overexpressed. It is associated with aggressive illness and a dismal prognosis. The TP53 gene is located on chromosome 17, and its deletion is a major bad prognostic factor. Loss of TP53, a critical tumor suppressor gene, is linked to reduced survival and resistance to traditional treatments. A prevalent anomaly in Multiple Myeloma (MM), deletion of chromosome 13q is frequently linked to worse outcomes, especially when it coexists with other high-risk cytogenetic abnormalities. When these numerical anomalies are seen alone, they are frequently linked to a better prognosis and can be seen in MM. However, other associated anomalies may have an impact on their prognosis. The complexity of multiple myopathies is attributed to genetic mutations and copy number variations, in addition to chromosomal abnormalities. Next-Generation Sequencing (NGS) technology has recently made various mutations that affect prognosis identifiable. These include mutations in two oncogenes, KRAS and NRAS, are commonly observed in MM patients and are linked to a dismal prognosis. They make the condition worse and make people less responsive to treatment. A proportion of MM patients have BRAF mutations, which are linked to an aggressive course of the disease.

Genes like Cyclin D1 (CCND1) and Myelocytomatosis Oncogene (MYC) overexpression are associated with poor prognosis and disease progression. In MM, cytogenetic anomalies are essential to risk classification. Cytogenetic abnormalities are used by the International Staging System (ISS) and the Revised International Staging System (R-ISS) to categorize patients into various risk groups. In general, patients with t(4;14), del(17p), and t(14;16) are considered high-risk. Reduced overall survival and a higher likelihood of progression have been connected to these anomalies. They frequently request for stricter surveillance and more rigorous treatment plans. Individuals with del(13q) and t(11;14) are typically regarded as intermediate-risk. The prognosis varies and depends on other factors like responsiveness to treatment and the existence of other chromosomal abnormalities.

Standard-risk patients frequently have trisomies and other less severe anomalies. These patients may respond well to conventional treatment modalities and typically have a better prognosis. Treatment plans for MM patients can be more effectively modified when cytogenetic abnormalities are understood. High-risk characteristics are being treated with more recent treatments that target certain disorders, such as monoclonal antibodies and proteasome inhibitors. Autologous Stem Cell Transplantation (ASCT) is a useful component of therapeutic regimens for high-risk patients. Based on cytogenetic results, precondition regimes and post-transplant therapeutic options may be modified.

Individuals with cytogenetic characteristics that increase risk may be qualified for clinical trials investigating new treatments and combinations. Participating in clinical trials improves the field and provides access to state-of-the-art medicines. It is essential to regularly monitor cytogenetic abnormalities in order to evaluate the course of the disease and the effectiveness of treatment. Cytogenetic profile changes throughout time are monitored using methods like Next-Generation Sequencing (NGS) and Fluorescence *In Situ* Hybridization (FISH). Giving individualized care and modifying treatment plans are made easier with the use of this information. The prognosis of multiple myeloma is largely dependent on cytogenetic abnormalities. Genetic mutations, deletions, and chromosomal translocations have a substantial influence on the course of the disease, how well it responds to therapy, and how long a patient lives. Technological developments in genomics have improved our knowledge of these anomalies and how they affect patient care. Clinicians can give patients with multiple myeloma more individualized and efficient care by incorporating cytogenetic data into risk assessment and therapy planning. In order to improve outcomes and further the treatment of this difficult condition, additional research into the molecular mechanisms behind these variations and the development of targeted medicines are possible.